CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 32.45×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
300.20MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4050xvs all stocks
52-Week Change
9.43%vs all stocks
Market Capitalization
300.20MUSDvs all stocks (USD)
Enterprise Value
147.23MUSDvs all stocks (USD)
Forward P/E
-3.48xvs Biotechnology peers
Price to Book (MRQ)
1.45xvs Biotechnology peers
Enterprise to EBITDA
-2.50xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.88%vs Biotechnology peers
Return on Equity (TTM)
-43.84%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-58.88MUSDvs all stocks (USD)
Net Income (TTM)
-54.44MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-49.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-33.19MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-59.38MUSDvs all stocks (USD)
Pre-tax Income
-56.02MUSDFY2025 · Dec 31, 2025Net Income
-56.02MUSDFY2025 · Dec 31, 2025EBIT
-59.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-59.02MUSDFY2025 · Dec 31, 2025Research & Development
42.05MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.04MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-56.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-48.93MUSDFY2025 · Dec 31, 2025Free Cash Flow
-49.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
128.65MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-56.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
353.78KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.31MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-400.80KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
833.66KUSDFY2025 · Dec 31, 2025Capital Expenditures
-142.23KUSDFY2025 · Dec 31, 2025Purchase of Investments
-88.60MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-88.74MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
225.79MUSDFY2025 · Dec 31, 2025Shares Outstanding
64.69MSharesUpdated Jul 19, 2026Float Shares
49.21MSharesUpdated Jul 19, 2026Shares Short
15.03MSharesUpdated Jul 19, 2026Short Ratio
6.99daysvs all stocks
Short % of Shares Outstanding
30.61%vs all stocks
% Held by Insiders
13.48%vs all stocks
% Held by Institutions
47.72%vs all stocks
Total Cash (MRQ)
156.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.42USDUpdated Jul 19, 2026Total Debt (MRQ)
3.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0181xvs Biotechnology peers
Current Ratio (MRQ)
32.45xvs Biotechnology peers
Book Value per Share (MRQ)
3.19USDUpdated Jul 19, 2026Total Assets
231.99MUSDvs all stocks (USD)
Total Current Assets
176.25MUSDFY2025 · Dec 31, 2025Total Liabilities
13.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
55.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.43MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
128.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
44.19MUSDFY2025 · Dec 31, 2025Accounts Payable
1.54MUSDFY2025 · Dec 31, 2025Short-term Debt
397.10KUSDFY2025 · Dec 31, 2025Other Current Liabilities
291.51KUSDFY2025 · Dec 31, 2025Long-term Debt
3.43MUSDFY2025 · Dec 31, 2025Common Stock (Book)
64.65KUSDFY2025 · Dec 31, 2025Retained Earnings
-280.32MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
218.48MUSDvs all stocks (USD)
52-Week Low
2.90USDUpdated Jul 19, 202652-Week High
10.08USDUpdated Jul 19, 202652-Week Change
9.43%vs all stocks
Beta
0.4050xvs all stocks
50-Day MA
4.84USDUpdated Jul 19, 2026200-Day MA
5.53USDUpdated Jul 19, 2026Avg 10-Day Volume
982.84KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.46MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.06USDUpdated Jul 19, 2026Other Income / Expense
311.67KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 32.45×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 32.45Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.75
Altman Z-Score 11.66: safe zoneNotable
Altman Z-Score: 11.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Ilika Plc
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
People.cn Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Shenzhen Sinovatio Technology Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity